Over 44,000 pounds of shrimp recalled due to possible listeria contamination
The United States Food and Drug Administration (FDA) announced the recall from Bornstein Seafoods Inc., which affects 44,550 pounds of shrimp, after a routine sampling detected listeria monocytogenes.
As noted by the Centers for Disease Control and Prevention (CDC), listeria is a 'bacteria that can contaminate many foods.' Although symptoms can vary, a listeria infection 'can cause invasive illness and intestinal illness.'
Listeria infection is the third leading cause of death from foodborne illness in the United States, killing roughly 260 people per year.
According to the FDA's report, the shrimp was sold in either one-pound or five-pound bags and was distributed to retailers in California, Oregon, Washington, and British Columbia of Canada.
The affected bags of shrimp are listed alongside the product's UPC code and lot number in the report. No illnesses have currently been reported.
All customers who have purchased the affected bags of shrimp are urged to return them to the place of purchase in exchange for a full refund. Any questions regarding the recall can be directed to the company using the email address Andrew@bornstein.com.
The recall came on the same day P. East Trading Corp. recalled its Salted Smoked Split Herring because it may have been contaminated with Clostridium botulinum, a bacterium that can cause illness or death.
Botulism is a rare but serious condition caused by a toxin that attacks the body's nerves. Symptoms include general weakness, dizziness, double-vision, trouble with speaking or swallowing, difficulty in breathing, abdominal distension, and constipation.
There have been no reported illnesses so far.
The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed.
Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Boston Globe
8 minutes ago
- Boston Globe
How hurricanes, fires, and floods put drugs and medical supplies at risk
Advertisement These threats are especially pressing as the Trump administration makes a push to ramp up US drug manufacturing, say the authors of the new research. As part of a broader effort to increase US pharmaceutical factories, President Donald Trump has threatened to impose tariffs on imported medicines, a move that could make the country more reliant on domestically produced supplies. Roughly 40% of finished medications and 80% of active pharmaceutical ingredient components come from abroad, according to US Food and Drug Administration estimates. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'Climate change-driven extreme weather events impose new threats to established vulnerabilities in the US drug supply,' the study's authors wrote. 'Those threats must be examined to be appropriately mitigated.' The analysis used FDA and Federal Emergency Management Agency databases to find drug production facilities in counties with major fire, hurricane, storm, tornado and flood events between 2019 and 2024. California, Florida and North Carolina were home to the largest numbers of facilities in counties with presidential disaster declarations. Advertisement Hurricanes were the most common of the climate-related disasters in areas with pharmaceutical facilities, according to the research. In 2017, Hurricane Maria hit Puerto Rico and disrupted Baxter's saline solution manufacturing facility there. Baxter is a major manufacturer of the sterile salt water widely used in hospitals to deliver medications and keep patients hydrated. The company didn't have backup facilities manufacturing smaller bags of the saline solution, which compounded pre-existing supply issues. Baxter has said it's learned from Maria and now has a more resilient supply chain, citing manufacturing investments and FDA clearance to produce saline outside of the US if needed. Even resilient supply chains are prone to climate shocks, though. Helene flooded Baxter's North Carolina facility, which made 60% of the IV fluid bags used in US hospitals for various functions, including to deliver medicine. Baxter reported earlier this year that the North Carolina plant was back at pre-hurricane production levels, and the FDA said this month that the shortages had resolved. Sarah Ryan, a spokesperson for pharmaceutical industry group PhRMA, says that the industry works with government regulators to avoid shortages. The new research did not determine how often such disasters result in shortages, saying that data wasn't readily available. ©2025 Bloomberg L.P.
Yahoo
27 minutes ago
- Yahoo
Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health
PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management. At a time when obesity and disease threaten the well-being of millions, Signos is leading the movement to put metabolic health back into the hands of individuals. By integrating Stelo by Dexcom glucose biosensor with an AI-powered platform for deciphering unique metabolisms, Signos enables people to see how food choices, timing, activity, stress, and even sleep affect their bodies in real time — equipping them with the information required to seize their health and make decisions backed by their own biology. "This is more than a product launch — it's a mission," said Sharam Fouladgar-Mercer, CEO and Founder of Signos. "Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen." Key Features and Purpose-Driven Benefits: Igniting the Metabolic Movement with Personalized Data: By tapping into the body's own signals, Signos equips individuals with tools to improve sleep, manage weight, and reduce the risk of chronic disease — not through restriction, but through understanding. Personalized, AI-Driven Insights: Signos translates glucose fluctuations into easy-to-follow, personalized recommendations — transforming raw data into actionable guidance for building healthier everyday habits. Total Body Intelligence: Signos helps users understand how their bodies respond to meals, workouts, sleep, and stress, creating a holistic picture of personal health. Expert Metabolic Monitoring: Signos removes barriers and puts powerful glucose insights into the hands of millions without the need for prescriptions, inflated prices, or hidden hoops. It's real-time metabolic health, made truly accessible. The need for accessible, effective metabolic health solutions has never been greater. With 73.6% of U.S. adults classified as overweight or obese, 88% of Americans classified as metabolically unhealthy, and global diabetes diagnoses projected to reach 1.3 billion by 2050, Signos offers a proactive solution grounded in science and is changing the trajectory of metabolic health by intervening early and guiding users toward meaningful, lasting lifestyle changes. The company aims to help millions monitor their metabolic health and build better habits by leveraging insights based on glucose, the body's primary energy source. Raven-Symoné, actress and advisor, shared, "I've been using Signos for years now and no matter my mental ups and downs it is there to keep me in reality. The reality is things change, levels change, but if you keep an eye on the overall picture you can keep your health in the green. Signos gives me the confidence to enjoy life while being mindful of my body and what it needs." Signos is available now, offering individuals everywhere a revolutionary way to monitor glucose, unlock personalized insights, and take control of their metabolism to build a sustainably healthier life — all from the convenience of their smartphone. For more information, visit View original content to download multimedia: SOURCE Signos
Yahoo
37 minutes ago
- Yahoo
FDA Says 'Do Not Eat or Serve' Certain Frozen Shrimp Sold at Walmart
The Food and Drug Administration (FDA) has advised the public "not to eat, sell, or serve" certain frozen shrimp from Indonesia that were sold at Walmart (WMT) because of potential contamination with radioactive material. The FDA said that the affected Great Value brand frozen raw shrimp products were processed by Indonesian firm PT. Bahari Makmur Sejati, or BMS Foods, and sold at Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas, and West Virginia. "At this time, no product that has tested positive or alerted for Cesium-137 (Cs-137) has entered the U.S. commerce," the FDA said Tuesday, adding that the shrimp was "in violation of the Federal Food, Drug, & Cosmetic Act," and that its investigation was ongoing. "If you recently purchased one of the impacted lots of Great Value raw frozen shrimp from Walmart, throw it away," the agency advised. "Do not eat or serve this product." "The health and safety of our customers is always a top priority," a Walmart spokesperson told Investopedia. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate." The retail giant added that customers in possession of the shrimp should discard it and visit any Walmart store for a full refund. Walmart shares were up about 1% in recent trading and have added 13% of their value this year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data